Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 94

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 94
---
2,761)                    Net cash used in operating activities(23,674)(51,161)Cash flows from investing activities  Cash assumed in acquisition of Old Cartesian— 6,561 Proceeds from maturities of marketable securities— 28,254 Purchases of property and equipment(9,093)(206)Proceeds from the sale of property and equipment351 —                     Net cash (used in) provided by investing activities(8,742)34,609 Cash flows from financing activities  Proceeds from issuance of Series A Preferred Stock, gross in private placement40,000 20,250 Repayments of principal, final payment fee, and prepayment penalty on debt— (27,457)Net proceeds from issuance of common stock and Series B Preferred Stock in private placement124,438 — Equity offering costs(66)— Proceeds from exercise of common warrants2,877 — Settlement of outstanding equity awards at Merger— (6,169)Proceeds from exercise of stock options1,179 — Proceeds from issuance of common stock under Employee Stock Purchase Plan— 231                     Net cash provided by (used in) financing activities168,428 (13,145)Effect of exchange rate changes on cash(21)(53)Net change in cash, cash equivalents, and restricted cash135,991 (29,750)Cash, cash equivalents, and restricted cash at beginning of period78,288 108,038 Cash, cash equivalents, and restricted cash at end of period$214,279 $78,288 Supplement cash flow information  Cash paid for interest$— $1,853 Non-cash investing and financing activities  Issuance of common stock, license agreement in stock-based compensation expense$— $1,500 Purchase of property and equipment not yet paid$847 $128 Equity offering costs in accrued liabilities$451 $— 

The accompanying notes are an integral part of these consolidated financial statements.

F-7